1. Scrip
  2. >>Business
  3. >>Financing

Cirius Suspects Insulin Resistance Is Underlying Key To NASH

 
• By Joseph Haas

The former Octeta is expanding the ongoing Phase IIb study of its second-generation insulin sensitizer. An insulin sensitizer with a better safety profile than first-generation drugs like Actos may provide a backbone therapy for NASH, the company believes.

With $40m in Series A cash and led by a new, experienced executive team, Cirius Therapeutics Inc. is expanding a Phase IIb dose-finding trial of its insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis (NASH) in the hopes that a safer, second-generation drug can address the disease's underlying metabolic pathology.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.